Crescent Biopharma Posts $24.8M Q2 Loss, Cash Runway Extended to H2 2028; Key Data Readouts in 2027
CBIO sits 69% above its 52-week low of $8.72.
Summary
Crescent Biopharma reported a smaller-than-expected net loss of $24.8 million for Q2 2026, with pro forma cash of $305.1 million following its recent $143.7 million public offering. The cash runway now extends into the second half of 2028, past multiple anticipated clinical catalysts. Enrollment is progressing in the ASCEND Phase 1/2 trial of CR-001, a PD-1 x VEGF bispecific antibody, with proof-of-concept data expected in Q1 2027. A Phase 2 combination trial with sac-TMT in NSCLC has begun in China, and initial data from that study is anticipated by mid-2027. The ADC pipeline is advancing, with CR-003 in Phase 1/2 and CR-002 on track to enter the clinic in H2 2026. This follows the July 14-16 public offering and the July 1 shelf registration, providing a clearer financial picture and clinical timeline.
At the time of this announcement, CBIO was trading at $14.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $545.9M. The 52-week trading range was $8.72 to $27.41. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.